Phase I, open-label, multi-center dose-finding and expansion study to investigate the safety, tolerability, and preliminary efficacy of CR-001 (5-FU-miR-15a) in patients with acute myeloid leukemia

Irini Ktoridou-Valen; Andrea Lenartova; Sturla Magnus Grøndal; Cara E. Wogsland; Adam S. Dowrick; Mark Wood; Knut T. Smerud; Nils Meland; Thomas Dahl; Andrew Fesler; Jingfang Ju; Bjørn T. Gjertsen

doi:10.1038/s41375-026-03054-6

Phase I, open-label, multi-center dose-finding and expansion study to investigate the safety, tolerability, and preliminary efficacy of CR-001 (5-FU-miR-15a) in patients with acute myeloid leukemia

Irini Ktoridou-Valen
, Andrea Lenartova
, Sturla Magnus Grøndal
, Cara E. Wogsland
, Adam S. Dowrick
, Mark Wood
, Knut T. Smerud
, Nils Meland
, Thomas Dahl
, Andrew Fesler
, Jingfang Ju
, Bjørn T. Gjertsen

University of Bergen
University of Oslo
KinN Therapeutics AS
Smerud Medical Research International AS
Curamir Therapeutics Inc.

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	2076-2080
Number of pages	5
Journal	Leukemia
Volume	40
Issue number	9
DOIs	https://doi.org/10.1038/s41375-026-03054-6
State	Published - Sep 2026

Access to Document

10.1038/s41375-026-03054-6

Cite this

Ktoridou-Valen, I., Lenartova, A., Grøndal, S. M., Wogsland, C. E., Dowrick, A. S., Wood, M., Smerud, K. T., Meland, N., Dahl, T., Fesler, A., Ju, J., & Gjertsen, B. T. (2026). Phase I, open-label, multi-center dose-finding and expansion study to investigate the safety, tolerability, and preliminary efficacy of CR-001 (5-FU-miR-15a) in patients with acute myeloid leukemia. Leukemia, 40(9), 2076-2080. https://doi.org/10.1038/s41375-026-03054-6

@article{80806060415b43cbb3cb8816ed009dfc,

title = "Phase I, open-label, multi-center dose-finding and expansion study to investigate the safety, tolerability, and preliminary efficacy of CR-001 (5-FU-miR-15a) in patients with acute myeloid leukemia",

author = "Irini Ktoridou-Valen and Andrea Lenartova and Gr{\o}ndal, \{Sturla Magnus\} and Wogsland, \{Cara E.\} and Dowrick, \{Adam S.\} and Mark Wood and Smerud, \{Knut T.\} and Nils Meland and Thomas Dahl and Andrew Fesler and Jingfang Ju and Gjertsen, \{Bj{\o}rn T.\}",

year = "2026",

month = sep,

doi = "10.1038/s41375-026-03054-6",

language = "English",

volume = "40",

pages = "2076--2080",

journal = "Leukemia",

issn = "0887-6924",

number = "9",

}

Ktoridou-Valen, I, Lenartova, A, Grøndal, SM, Wogsland, CE, Dowrick, AS, Wood, M, Smerud, KT, Meland, N, Dahl, T, Fesler, A, Ju, J & Gjertsen, BT 2026, 'Phase I, open-label, multi-center dose-finding and expansion study to investigate the safety, tolerability, and preliminary efficacy of CR-001 (5-FU-miR-15a) in patients with acute myeloid leukemia', Leukemia, vol. 40, no. 9, pp. 2076-2080. https://doi.org/10.1038/s41375-026-03054-6

Phase I, open-label, multi-center dose-finding and expansion study to investigate the safety, tolerability, and preliminary efficacy of CR-001 (5-FU-miR-15a) in patients with acute myeloid leukemia. / Ktoridou-Valen, Irini; Lenartova, Andrea; Grøndal, Sturla Magnus et al.
In: Leukemia, Vol. 40, No. 9, 09.2026, p. 2076-2080.

Research output: Contribution to journal › Letter › peer-review

TY - JOUR

T1 - Phase I, open-label, multi-center dose-finding and expansion study to investigate the safety, tolerability, and preliminary efficacy of CR-001 (5-FU-miR-15a) in patients with acute myeloid leukemia

AU - Ktoridou-Valen, Irini

AU - Lenartova, Andrea

AU - Grøndal, Sturla Magnus

AU - Wogsland, Cara E.

AU - Dowrick, Adam S.

AU - Wood, Mark

AU - Smerud, Knut T.

AU - Meland, Nils

AU - Dahl, Thomas

AU - Fesler, Andrew

AU - Ju, Jingfang

AU - Gjertsen, Bjørn T.

PY - 2026/9

Y1 - 2026/9

UR - https://www.scopus.com/pages/publications/105045043611

U2 - 10.1038/s41375-026-03054-6

DO - 10.1038/s41375-026-03054-6

M3 - Letter

AN - SCOPUS:105045043611

SN - 0887-6924

VL - 40

SP - 2076

EP - 2080

JO - Leukemia

JF - Leukemia

IS - 9

ER -

Phase I, open-label, multi-center dose-finding and expansion study to investigate the safety, tolerability, and preliminary efficacy of CR-001 (5-FU-miR-15a) in patients with acute myeloid leukemia

Access to Document

Other files and links

Fingerprint

Cite this